KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Weighted Average): 2012-2024

Historic Shares Outstanding (Weighted Average) for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $78.0 million.

  • Travere Therapeutics' Shares Outstanding (Weighted Average) rose 16.53% to $89.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.1 million, marking a year-over-year increase of 16.53%. This contributed to the annual value of $78.0 million for FY2024, which is 3.86% up from last year.
  • Per Travere Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $78.0 million for FY2024, which was up 3.86% from $75.1 million recorded in FY2023.
  • Over the past 5 years, Travere Therapeutics' Shares Outstanding (Weighted Average) peaked at $78.0 million during FY2024, and registered a low of $51.1 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $72.5 million, with a median of $75.1 million in 2023.
  • Data for Travere Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 19.93% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Travere Therapeutics' Shares Outstanding (Weighted Average) stood at $51.1 million in 2020, then increased by 19.93% to $61.2 million in 2021, then rose by 4.81% to $64.2 million in 2022, then increased by 17.10% to $75.1 million in 2023, then grew by 3.86% to $78.0 million in 2024.